BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37735430)

  • 21. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
    Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
    Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
    Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
    Gurney M; Chekkaf I; Baranwal A; Basmaci R; Katamesh B; Greipp P; Foran JM; Badar T; Mangaonkar AA; Begna KH; Gangat N; Patnaik MM; Litzow MR; Shah MV; Viswanatha DS; He R; Alkhateeb HB; Al-Kali A
    Br J Haematol; 2023 Jul; 202(2):279-283. PubMed ID: 37144345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
    Gurule NJ; Malcolm KC; Harris C; Knapp JR; O'Connor BP; McClendon J; Janssen WJ; Lee FFY; Price C; Osaghae-Nosa J; Wheeler EA; McMahon CM; Pietras EM; Pollyea DA; Alper S
    Leukemia; 2023 Oct; 37(10):2115-2124. PubMed ID: 37591942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
    Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
    Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
    Akef A; McGraw K; Cappell SD; Larson DR
    PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
    Bănescu C; Tripon F; Muntean C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies.
    Biancon G; Joshi P; Zimmer JT; Hunck T; Gao Y; Lessard MD; Courchaine E; Barentine AES; Machyna M; Botti V; Qin A; Gbyli R; Patel A; Song Y; Kiefer L; Viero G; Neuenkirchen N; Lin H; Bewersdorf J; Simon MD; Neugebauer KM; Tebaldi T; Halene S
    Mol Cell; 2022 Mar; 82(6):1107-1122.e7. PubMed ID: 35303483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.
    Gao Y; Jia M; Mao Y; Cai H; Jiang X; Cao X; Zhou D; Li J
    Am J Clin Pathol; 2022 May; 157(5):691-700. PubMed ID: 34664628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
    Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X; Song X; Yan X
    Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.